Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High-Risk Non-Muscle Invasive Bladder Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02281383
What this trial is testing

Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer

Who this might be right for
Bladder CancerHigh Risk Superficial
Memorial Sloan Kettering Cancer Center 80
Large-scale testing (Phase 3)WithdrawnNCT07551544
What this trial is testing

ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer

Who this might be right for
NMIBC
ImmunityBio, Inc.
Post-approval studies (Phase 4)Looking for participantsNCT05962541
What this trial is testing

Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)

Who this might be right for
Non-muscle-invasive Bladder CancerNon-Muscle Invasive Bladder Urothelial CarcinomaHigh Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
University of Roma La Sapienza 327
Testing effectiveness (Phase 2)Study completedNCT03636256
What this trial is testing

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

Who this might be right for
Bladder CancerUrothelial CarcinomaUrinary Bladder Neoplasm+6 more
NanOlogy, LLC 36
Testing effectiveness (Phase 2)Study completedNCT02015104
What this trial is testing

Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG

Who this might be right for
Bladder Cancer
National Cancer Institute (NCI) 32
Early research (Phase 1)Study completedNCT03191578
What this trial is testing

Immunological Response to Intravesical BCG Therapy of Superficial Bladder Cancer by Prior Administration of RUTI®

Who this might be right for
High-Risk Non-Muscle-Invasive Bladder Cancer
Archivel Farma S.L. 44
Large-scale testing (Phase 3)UnknownNCT04490993
What this trial is testing

Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients

Who this might be right for
Non-muscle Invasive Bladder Cancer
Jiangsu Yahong Meditech Co., Ltd aka Asieris 359
Early research (Phase 1)Active Not RecruitingNCT05843448
What this trial is testing

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Who this might be right for
High Risk Non-Muscle Invasive Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8Stage 0is Bladder Cancer AJCC v8+1 more
University of California, Davis 6
Early research (Phase 1)Study completedNCT06350838
What this trial is testing

Clinical Study to Investigate the Safety and Tolerance of Therapeutic BCG in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC)

Who this might be right for
Non-muscular Invasive Bladder Cancer
Chengdu CoenBiotech Co., Ltd 10
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07808216
What this trial is testing

Toripalimab Combined With Intravesical Gemcitabine as Adjuvant Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer After TURBT

Who this might be right for
Non Muscle Invasive Bladder Cancer
Tianjin First Central Hospital 54
Large-scale testing (Phase 3)Not Yet RecruitingNCT07198451
What this trial is testing

Efficacy of Gemcitabine Submucosal Injection for Preventing Recurrence in Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Randomized Trial

Who this might be right for
Non Muscle Invasive Bladder Cancer
Shanghai University of Traditional Chinese Medicine 320
Early research (Phase 1)Looking for participantsNCT07483970
What this trial is testing

A Phase I/II Study of JL19001 Injection Alone or in Combination With BCG in Subjects With High Risk Non-Muscle Invasive Bladder Cancer.

Who this might be right for
High Risk Non-muscle Invasive Bladder Cancer
Jecho Biopharmaceuticals Co., Ltd. 18
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07189793
What this trial is testing

Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study

Who this might be right for
Urinary Bladder NeoplasmsCarcinoma, Transitional CellCarcinoma in Situ of Bladder+1 more
First Affiliated Hospital of Wenzhou Medical University 106
Post-approval studies (Phase 4)Study completedNCT02214602
What this trial is testing

Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer

Who this might be right for
Carcinoma of Urinary Bladder, Superficial
Mansoura University 240
Large-scale testing (Phase 3)Looking for participantsNCT07480356
What this trial is testing

Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder (Urothelial, Transitional Cell) CancerNon-Muscle Invasive Bladder CarcinomaNon-muscle Invasive Bladder Cancer With Carcinoma in Situ
Protara Therapeutics 284
Large-scale testing (Phase 3)Active Not RecruitingNCT05704244
What this trial is testing

Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)

Who this might be right for
Bladder Cancer
Ferring Pharmaceuticals 25
Not applicableStudy completedNCT04319263
What this trial is testing

Oncological Outcomes of Different Patterns of Tumor Recurrence at First Evaluation After Bacillus Calmette-Guérin Induction Therapy for Intermediate and High Risk Non Muscle Invasive Bladder Cancer

Who this might be right for
Bladder Cancer
Mansoura University 1,600
Large-scale testing (Phase 3)Active Not RecruitingNCT03799835
What this trial is testing

Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients

Who this might be right for
Bladder Cancer
UNICANCER 517
Testing effectiveness (Phase 2)Active Not RecruitingNCT06187506
What this trial is testing

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

Who this might be right for
Non-muscle Invasive Bladder CancerHER-2 Protein Overexpression
Fudan University 20
Early research (Phase 1)Active Not RecruitingNCT06181266
What this trial is testing

A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer

Who this might be right for
NMIBCHigh Risk NMIBCNon Muscle Invasive Bladder Cancer
Prokarium Ltd 22
Next Page